This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
A nebulized lipopeptide fusion inhibitor delivered to monkey lungs was safe and protected 2 of 5 monkeys from lethal Nipah virus infection, with all treated animals showing delayed disease and preserved immune cells.
Why it matters
Nipah virus has no approved treatment or vaccine and kills up to 75% of those infected. An inhaled antiviral peptide that can be given quickly after exposure could fill a critical gap in pandemic preparedness.
The numbers in context
3 nebulized doses every 24 hours. Peptide deposited across multiple lung regions. 2 of 5 treated monkeys survived lethal NiV-Bangladesh challenge. No toxicity or adverse hematological/biochemical effects.
How the study worked
Aerosol delivery optimization using 3D respiratory model. Safety assessment in African green monkeys. Lethal Nipah-Bangladesh challenge study with peptide-treated vs. control monkeys.
Who was studied
African green monkeys challenged with lethal Nipah-Bangladesh virus
What this study cannot tell us
Only 2 of 5 monkeys fully protected. Small sample typical of BSL-4 primate studies. First-generation lipopeptide; next-generation versions being developed. Prophylactic dosing only, not post-exposure treatment.
Read the original research
Development of nebulized inhalation delivery for fusion-inhibitory lipopeptides to protect non-human primates against Nipah-Bangladesh infection.
Antiviral research, 235, 106095
Citation
Reynard, Olivier; Iampietro, Mathieu; Dumont, Claire; Le Guellec, Sandrine; Durand, Stephanie; Moroso, Marie; Brisebard, Elise; Dhondt, Kévin P; Pelissier, Rodolphe; Mathieu, Cyrille; Cabrera, Maria; Le Pennec, Deborah; Amurri, Lucia; Alabi, Christopher; Cardinaud, Sylvain; Porotto, Matteo; Moscona, Anne; Vecellio, Laurent; Horvat, Branka. (2025). Development of nebulized inhalation delivery for fusion-inhibitory lipopeptides to protect non-human primates against Nipah-Bangladesh infection.. Antiviral research, 235, 106095. https://doi.org/10.1016/j.antiviral.2025.106095